Aquinox Pharmaceuticals, Inc. (AQXP) Raised to Hold at BidaskClub
BidaskClub upgraded shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) from a sell rating to a hold rating in a research report sent to investors on Friday morning.
Other equities analysts have also issued reports about the stock. Cantor Fitzgerald set a $28.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, May 9th. Zacks Investment Research upgraded shares of Aquinox Pharmaceuticals from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research report on Thursday, May 11th. Finally, ValuEngine upgraded shares of Aquinox Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, June 2nd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Aquinox Pharmaceuticals currently has an average rating of Buy and an average target price of $22.50.
Aquinox Pharmaceuticals (AQXP) opened at 14.92 on Friday. Aquinox Pharmaceuticals has a 1-year low of $8.04 and a 1-year high of $19.97. The company has a 50 day moving average of $14.46 and a 200 day moving average of $15.62. The firm’s market capitalization is $349.47 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Tuesday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.15. During the same quarter in the previous year, the business earned ($0.39) EPS. Analysts forecast that Aquinox Pharmaceuticals will post ($2.05) EPS for the current year.
WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/07/aquinox-pharmaceuticals-inc-aqxp-raised-to-hold-at-bidaskclub.html.
In related news, insider David Main sold 15,625 shares of Aquinox Pharmaceuticals stock in a transaction on Monday, June 5th. The shares were sold at an average price of $13.26, for a total value of $207,187.50. Following the transaction, the insider now directly owns 77,530 shares in the company, valued at approximately $1,028,047.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.70% of the company’s stock.
A number of institutional investors have recently bought and sold shares of AQXP. Bank of New York Mellon Corp raised its position in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares during the period. Alps Advisors Inc. increased its stake in Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after buying an additional 939 shares during the period. Investment Centers of America Inc. acquired a new stake in Aquinox Pharmaceuticals during the first quarter worth approximately $172,000. Finally, Geode Capital Management LLC increased its stake in Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after buying an additional 11,035 shares during the period. Hedge funds and other institutional investors own 98.32% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.